Growth • Aldeyra Therapeutics
ALDX
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
0%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
0%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
0%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
0%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
0%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!